Altered gene expression due to aberrant DNA methylation correlates with responsiveness to anti-EGFR antibody treatment.

ABSTRACT: The cetuximab gene expression signature and DNA methylation status of colorectal cancer (CRC) are predictive of the therapeutic effects of anti-epidermal growth factor receptor (EGFR) antibody therapy. As DNA methylation is a means of regulating gene expression, it may play an important role in the expression of cetuximab signature genes. This study aims to determine the effects of aberrant DNA methylation on the regulation of cetuximab signature gene expression. Comprehensive DNA methylation and gene expression data were retrieved from CRC patients in three tumor tissue (TT) cohorts and three normal colorectal mucosa/tumor tissue paired (NCM-TT) cohorts. Of the 231 cetuximab signature genes, 57 exhibited an inverse correlation between the methylation of promoter CpG sites and gene express

SUBMITTER: Otsuki Y 

PROVIDER: S-EPMC9459254 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature